Schedule 13G ownership disclosure

Cullinan Therapeutics Inc

Common Stock, par value $0.0001 per share · CUSIP: 230031106

Event date: 2025-09-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • LYNX1 CAPITAL MANAGEMENT LP

    Shares: 5,766,090.00 · Class: 9.8%

  • WESTON NICHOLS

    Shares: 5,766,090.00 · Class: 9.8%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000902664-25-004966
Form type
SCHEDULE 13G/A
Filer
Cullinan Therapeutics, Inc.
CIK
CIK 1789972
Filed
Nov 14, 2025
Reporting period
Sep 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub